Compare Stocks: CTNM, BHC, HRMY, and MLYS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$6.79 -0.6%	$5.66	$4.33 ▼ $8.00	$2.56B	0.37	2.97 million shs	2.16 million shs
CTNM Contineum Therapeutics	$17.57 +1.9%	$15.31	$8.60 ▼ $17.79	$648.59M	0.75	565,886 shs	320,781 shs
HRMY Harmony Biosciences	$41.86 -2.3%	$37.46	$25.52 ▼ $43.49	$2.50B	0.93	649,129 shs	1.10 million shs
MLYS Mineralys Therapeutics	$28.27 -2.7%	$26.99	$22.30 ▼ $47.65	$2.57B	0.68	861,707 shs	1.33 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	-0.80%	+7.71%	+4.86%	+26.33%	-7.81%
CTNM Contineum Therapeutics	+1.91%	+1.86%	+10.50%	+52.92%	+66.07%
HRMY Harmony Biosciences	-2.33%	+4.99%	+7.94%	+30.00%	+11.54%
MLYS Mineralys Therapeutics	-2.65%	+8.69%	+6.68%	+19.33%	-3.35%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$6.79 -0.6%	$5.66	$4.33 ▼ $8.00	$2.56B	0.37	2.97 million shs	2.16 million shs
CTNM Contineum Therapeutics	$17.57 +1.9%	$15.31	$8.60 ▼ $17.79	$648.59M	0.75	565,886 shs	320,781 shs
HRMY Harmony Biosciences	$41.86 -2.3%	$37.46	$25.52 ▼ $43.49	$2.50B	0.93	649,129 shs	1.10 million shs
MLYS Mineralys Therapeutics	$28.27 -2.7%	$26.99	$22.30 ▼ $47.65	$2.57B	0.68	861,707 shs	1.33 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	-0.80%	+7.71%	+4.86%	+26.33%	-7.81%
CTNM Contineum Therapeutics	+1.91%	+1.86%	+10.50%	+52.92%	+66.07%
HRMY Harmony Biosciences	-2.33%	+4.99%	+7.94%	+30.00%	+11.54%
MLYS Mineralys Therapeutics	-2.65%	+8.69%	+6.68%	+19.33%	-3.35%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Cos	1.86	Reduce	$8.00	17.82% Upside
CTNM Contineum Therapeutics	2.40	Hold	$20.25	15.25% Upside
HRMY Harmony Biosciences	2.36	Hold	$47.11	12.54% Upside
MLYS Mineralys Therapeutics	2.44	Hold	$49.33	74.51% Upside

Current Analyst Ratings Breakdown

Latest CTNM, BHC, HRMY, and MLYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	HRMY Harmony Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$60.00
8/20/2026	BHC Bausch Health Cos	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/17/2026	HRMY Harmony Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/13/2026	MLYS Mineralys Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/11/2026	HRMY Harmony Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/5/2026	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$39.00
8/5/2026	HRMY Harmony Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$29.00 ➝ $34.00
8/5/2026	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$37.00
8/4/2026	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$70.00
8/4/2026	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $50.00
7/31/2026	BHC Bausch Health Cos	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Cos	$10.27B	0.25	$7.22 per share	0.94	($2.14) per share	-3.17
CTNM Contineum Therapeutics	$50M	13.22	N/A	N/A	$6.37 per share	2.76
HRMY Harmony Biosciences	$868.45M	2.81	$3.11 per share	13.48	$17.16 per share	2.44
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$6.23 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Cos	$157M	-$2.96	N/A	1.69	N/A	-10.12%	-561.95%	6.31%	10/28/2026 (Estimated)
CTNM Contineum Therapeutics	-$59.98M	-$1.73	N/A	N/A	N/A	N/A	-24.73%	-23.51%	10/29/2026 (Estimated)
HRMY Harmony Biosciences	$158.69M	$3.08	13.59	10.52	0.40	18.88%	20.06%	14.15%	11/3/2026 (Estimated)
MLYS Mineralys Therapeutics	-$154.65M	-$4.24	N/A	N/A	N/A	N/A	-57.97%	-54.15%	11/9/2026 (Estimated)

Latest CTNM, BHC, HRMY, and MLYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	MLYS Mineralys Therapeutics	-$0.5486	-$2.85	-$2.3014	-$2.85	N/A	N/A
8/4/2026	Q2 2026	HRMY Harmony Biosciences	$0.9560	$1.28	+$0.3240	$1.28	$250.77 million	$261.28 million
7/30/2026	Q2 2026	CTNM Contineum Therapeutics	-$0.4488	-$0.40	+$0.0488	-$0.40	N/A	N/A
7/29/2026	Q2 2026	BHC Bausch Health Cos	$0.96	$1.26	+$0.30	$0.68	$2.59 billion	$2.83 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Cos	54.68	1.44	1.08
CTNM Contineum Therapeutics	N/A	37.17	37.17
HRMY Harmony Biosciences	0.13	3.48	3.45
MLYS Mineralys Therapeutics	0.18	34.46	34.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Cos	78.65%
CTNM Contineum Therapeutics	N/A
HRMY Harmony Biosciences	86.23%
MLYS Mineralys Therapeutics	84.46%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Cos	20.67%
CTNM Contineum Therapeutics	7.90%
HRMY Harmony Biosciences	11.00%
MLYS Mineralys Therapeutics	18.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Cos	20,300	374.13 million	296.80 million	Optionable
CTNM Contineum Therapeutics	31	37.62 million	34.65 million	N/A
HRMY Harmony Biosciences	200	58.24 million	51.83 million	Optionable
MLYS Mineralys Therapeutics	28	88.41 million	71.66 million	Optionable

CTNM, BHC, HRMY, and MLYS Headlines

Recent News About These Companies

Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision

September 3 at 4:25 PM | seekingalpha.com

Pale Fire Capital SE Buys 248,658 Shares of Mineralys Therapeutics, Inc. $MLYS

September 3 at 6:08 AM | marketbeat.com

Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 7.5% - Should You Buy?

September 2 at 12:40 PM | marketbeat.com

Man Group plc Invests $1.61 Million in Mineralys Therapeutics, Inc. $MLYS

September 2 at 4:47 AM | marketbeat.com

Mineralys Therapeutics, Inc. $MLYS Shares Sold by Montanova Capital LLC

September 1 at 6:07 AM | marketbeat.com

Canada Pension Plan Investment Board Buys New Holdings in Mineralys Therapeutics, Inc. $MLYS

September 1 at 3:43 AM | marketbeat.com

820,481 Shares in Mineralys Therapeutics, Inc. $MLYS Purchased by Nantahala Capital Management LLC

August 29, 2026 | marketbeat.com

Deutsche Bank AG Takes $1.59 Million Position in Mineralys Therapeutics, Inc. $MLYS

August 29, 2026 | marketbeat.com

BlackRock Inc. Buys New Position in Mineralys Therapeutics, Inc. $MLYS

August 29, 2026 | marketbeat.com

Artia Global Partners LP Invests $3.72 Million in Mineralys Therapeutics, Inc. $MLYS

August 27, 2026 | marketbeat.com

Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

August 26, 2026 | globenewswire.com

Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 7,437 Shares of Stock

August 26, 2026 | insidertrades.com

ADAR1 Capital Management LLC Buys New Position in Mineralys Therapeutics, Inc. $MLYS

August 26, 2026 | marketbeat.com

Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 7,437 Shares of Stock

August 25, 2026 | marketbeat.com

380,354 Shares in Mineralys Therapeutics, Inc. $MLYS Bought by Parkman Healthcare Partners LLC

August 25, 2026 | marketbeat.com

Algert Global LLC Purchases 388,763 Shares of Mineralys Therapeutics, Inc. $MLYS

August 25, 2026 | marketbeat.com

HC Wainwright Has Bullish Estimate for MLYS Q3 Earnings

August 24, 2026 | americanbankingnews.com

HC Wainwright Issues Positive Outlook for MLYS Earnings

August 24, 2026 | marketbeat.com

Mineralys Therapeutics Earnings Call: Launch Prep vs. Costs

August 23, 2026 | tipranks.com

Timothy G. Youngquist 2020 Irrevocable Trust Takes $2.72 Million Position in Mineralys Therapeutics, Inc. $MLYS

August 19, 2026 | marketbeat.com

Mineralys (MLYS) Q2 2026 Earnings Call Transcript

August 18, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, BHC, HRMY, and MLYS Company Descriptions

Bausch Health Cos NYSE:BHC

$6.79 -0.04 (-0.59%)

As of 09/3/2026 03:58 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Contineum Therapeutics NASDAQ:CTNM

$17.57 +0.33 (+1.91%)

As of 09/3/2026 04:00 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Harmony Biosciences NASDAQ:HRMY

$41.86 -1.00 (-2.33%)

As of 09/3/2026 04:00 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Mineralys Therapeutics NASDAQ:MLYS

$28.27 -0.77 (-2.65%)

As of 09/3/2026 04:00 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTNM, BHC, HRMY, and MLYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTNM, BHC, HRMY, and MLYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTNM, BHC, HRMY, and MLYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, BHC, HRMY, and MLYS Company Descriptions

Bausch Health Cos NYSE:BHC

Contineum Therapeutics NASDAQ:CTNM

Harmony Biosciences NASDAQ:HRMY

Mineralys Therapeutics NASDAQ:MLYS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTNM, BHC, HRMY, and MLYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTNM, BHC, HRMY, and MLYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTNM, BHC, HRMY, and MLYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, BHC, HRMY, and MLYS Company Descriptions

Bausch Health Cos NYSE:BHC

Contineum Therapeutics NASDAQ:CTNM

Harmony Biosciences NASDAQ:HRMY

Mineralys Therapeutics NASDAQ:MLYS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools